Category: Webinar Series, .💰Free for Renewed Members💰, All Specialties Category: Webinar Series, .💰Free for Renewed Members💰, All Specialties (show less)

PLEASE BE ADVISED THAT YOU WILL HAVE 90 DAYS TO COMPLETE THIS COURSE FROM THE DATE OF PURCHASE.

Alzheimer’s disease is a leading cause of disability and morbidity in the United States. According to the Alzheimer’s Association, 580,000 Floridians aged 65 and older are living with Alzheimer’s. Timely diagnosis and treatment can be challenging, but there are clinical tools, biomarkers, and strategies to support accuracy and best practices. This webinar will highlight the necessary elements for accurate diagnosis and provide the latest clinical evidence on available and emerging therapies.

At the end of the presentation, learners will be able to:

• Describe the key necessary diagnostic clinical and biomarkers required for the accurate diagnosis of Alzheimer's disease
• Recognize recent FDA-approved disease modifying therapies
• Discuss the therapies currently being researched for Alzheimer’s disease

 Disclosure: 

•  The planners of this activity have nothing to disclose.  
• The presenter, Dr. Paul Winner disclosed the following relevant financial relationships:
  • Grant/Research Supporr: AbbVie, Acadia, Alzheon, Athira, Avinar, Biogen, Cassava, Eisia, Gem Vax, Lilly, Novartis, Novo Nordisk, Pfizer, Prothena, Sanofi, Roche, and Vaccinex
  • Consultant: Athira and Lilly
• These relationships have been mitigated.

   
 Estimated time to complete this educational activity: One hour  
   
 Issue date for this activity: June 26, 2024  
 Expiration date for this activity: December 31, 2026
   
 Instructions for earning credit: Learner must listen to the entire recorded webinar and complete the required post-assessment.